Oracle Speeds Clinical Trials with Quorum Integration

44
https://www.oracle.com/corporate/pressrelease/oracle-quorum-integration-021919.html

Originally Posted in Oracle 

 

Delays in institutional review board (IRB) approvals often complicate clinical research and development and delay the introduction of new therapies to market. Such bottlenecks pose additional obstacles in an industry plagued by rising development costs and increasing complexities. Out-of-the-box integration between Quorum and Oracle Health Sciences goBalto Activate cloud service addresses the inefficiencies associated with submission errors and lengthy IRB submission review cycles.

Research indicates that principal investigators spend nearly half (42 percent) of their time dealing with “administrative burdens.”  This is a category in which IRB-related issues weigh heavily, with one third of that lost time emanating from researcher omissions and errors. IRB review takes up to 2.9 percent of the total time devoted to a study and represents up to 4.7 percent of study costs.

With the integration, country-specific workflows and a management-based approach to site activation in goBalto Activate creates seamless communication with Quorum. This eliminates the need to send IRB submission documents via traditional, error-prone, manual forms of communication. The integrated connection enables Quorum to push approval documents directly into Activate workflows, automatically triggering alerts and thereby saving significant time. Study teams benefit from point-and-click submission of packages, seamless data transfers and the confidence that their submission was completed.

“Quorum is proud to collaborate with Oracle Health Sciences on this critical industry need,” said Cami Gearhart, CEO of Quorum. “This collaboration aligns with our customer promise of providing exceptional service through One-Touch Collaboration™, by continuing to be a partner of choice for agile and innovative ethics review services while maintaining the highest quality of human subject protections.”

“Quorum joins other leading organizations that are committed to modernizing and rethinking how clinical trials are initiated,” said Steve Rosenberg, general manager, Oracle Health Sciences. “Automation has become critical for reducing the costs and complexities of clinical trials and this new level of integration eliminates time consuming processes and improves operational efficiencies by addressing an entrenched bottleneck in the initiation process.”

By enabling global anytime, anywhere access to purpose-built study startup technology Oracle Health Sciences brings measurable change to the inception of a trial. The adoption of this solution will help shorten cycle times, reduce study costs and, most importantly, speed the delivery of new therapies to patients.